About this medicine
Product information is provided to support understanding and conversations with your care team. Follow the approved leaflet and your prescriber’s instructions.
Content migrated from the company website; pending clinical review before final publication.
Dosage forms
Oral tablets (200 mg)
Drug class
Multikinase tyrosine kinase inhibitor
Administration
Take 400 mg twice daily, at least one hour before or two hours after food.
Uses
• Hepatocellular carcinoma (HCC): first-line treatment of unresectable HCC
• Renal cell carcinoma (RCC): second-line treatment after progression on other treatments
• Differentiated thyroid cancer (DTC): disease resistant to radioactive iodine
Competitive advantages
As a multikinase tyrosine kinase inhibitor, sorafenib not only inhibits VEGF pathways but also affects the RAF/MEK/ERK pathway, reducing cancer-cell growth and proliferation.
This medicine is one of the early treatment-line options for patients with advanced liver cancer and has substantially increased survival. Sorafenib has been effective in controlling liver, kidney and thyroid cancers resistant to conventional treatment.
Original company product page ↗